NAFLD
The FDA supports a biomarker for aggressive fibrotic tumors
SG Tylor
Source: Nordic Bio The FDA has granted its backing to a blood test that may be able to determine if ...
At EASL 2023, Merck will present data on the investigational GLP-1/glucagon receptor co-agonist Efinopegdutide (MK-6024) in patients with non-alcoholic fatty liver disease (NAFLD)
SG Tylor
Source- Merck NJ-RAHWAY Efinopegdutide (MK-6024), an investigational GLP-1/glucagon receptor co-agonist, has new findings that have been accepted for oral presentation ...
